CJC-1295 with DAC (Drug Affinity Complex) is the long-acting version of the modified growth hormone-releasing hormone analog. The DAC component consists of a maleimidopropionyl group attached to a lysine residue that allows the peptide to covalently bind to serum albumin after injection. This albumin binding dramatically extends the half-life from minutes to approximately 8 days, allowing for once or twice weekly administration. The sustained elevation of GH and IGF-1 levels makes this version suitable for long-term research applications requiring consistent anabolic signaling. CJC-1295 with DAC maintains pulsatile GH release while providing sustained baseline elevation.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 6-8 days |
| Administration | Subcutaneous injection |
| Typical Dosage | 1-2 mg per week |
| Molecular Weight | 3,647.28 Da (with DAC linker) |
| Molecular Formula | C165H269N47O46 |
GHRH analog with DAC modification allowing albumin binding, creating depot effect for prolonged GH release.
All information is presented for Research Use Only (RUO). Not medical advice.